Figure 1From: Clinical outcome, biochemical and therapeutic follow-up in 14 Austrian patients with Long-Chain 3-Hydroxy Acyl CoA Dehydrogenase Deficiency (LCHADD) CK and liver enzymes in the four patients treated with heptanoate (start marked with red arrows). a: CK concentrations in Patient 2 before and after the introduction to therapy with heptanoate. b: CK concentrations and start of heptanoate in Patient 4. c: CK concentrations (left) and liver enzymes tests (right) before and after introduction of heptanoate in Patient 6. d: CK concentrations and start of heptanoate in Patient 8.Back to article page